First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype

Table 1 Serum pepsinogen level and Helicobacter pylori eradication in the extensive metabolizer group (CYP2C19 genotype: *1/*1)

Case	Age	Sex	PG I/II				UBT	Eradication
			Before eradication		After eradication
E1	45	F	3.6	-	5.0	-	0.1	○
E2	39	M	3.3	-	6.7	-	0.4	○
E3	59	M	3.1	-	5.2	-	0.5	○
E4	58	M	2.9	-	7.1	-	0.4	○
E5	50	F	2.2	1+	5.1	-	0.3	○
E6	43	F	2.2	1+	4.9	-	0.3	○
E7	63	F	1.6	1+	4.1	-	0.0	○
E8	56	F	2.8	2+	4.1	-	0.3	○
E9	36	F	2.2	2+	4.6	-	0.0	○
E10	75	F	2.5	2+	4.8	-	0.9	○
E11	67	M	3.7	-	2.2	2+	0.0	○
E12	64	M	0.8	3+	2.2	2+	1.3	○
E13	48	M	3.4	-	3.1	-	12.7	×
E14	50	F	4.3	-	6.4	-	12.7	×
E15	67	M	3.5	-	3.7	-	41.6	×
E16	34	F	3.0	-	3.4	-	19.5	×
E17	63	M	3.1	-	3.0	-	26.8	×
E18	71	F	1.2	3+	3.1	-	11.0	×
E19	55	M	2.4	1+	2.6	1+	24.6	×
E20	56	M	2.0	2+	2.2	1+	24.9	×
E21	80	M	1.7	2+	1.8	2+	20.9	×
E22	53	M	2.2	2+	2.2	2+	26.6	×
E23	43	F	2.2	2+	2.3	2+	11.5	×

(-), PG I ≥ 70 ng/mL and PG I/PG II ratio ≥ 3.0; (1+), PG I < 70 ng/mL and PG I/PG II ratio < 3.0; (2+), PG I < 50 ng/mL and PG I/PG II ratio < 3.0; (3+), PG I < 30 ng/mL and PG I/PG II ratio < 2.0. Eradication (○) rate = 12/23 (52.2%). M: Male; F: Female; PG: Pepsinogen; UBT: ¹³C-urea breath test.